and thank you this progress the on issued a R&D we a commercial refinancing, Scott we debt call. of which our discuss joining. all will in for recent more provided on release of afternoon, press number and In performance, we today's important all updates Thanks, detail
leadership years Will I look contributions in being like already I Officer. early his begin, ahead. us important joined Andrews, organization. presence is Medical to the would Chief in and to and our to However, officially welcome, the felt new Will forward And July across his
$XXX solid quarter. result are with difference patients that expectations the sales second million is $XX.X knee over $XXX in was in confronting a in of real full the second we pain. we first we to ZILRETTA net This to Moving performance, XX% our barring and Stated impact our unanticipated COVID-XX quarter, for half. makes range ZILRETTA a million represents which of million, commercial product the from year any during line in simply, the reiterating our growth sales guidance recorded believe ZILRETTA OA
we They've executing to them Our that on. and exactly are ensure team making focused that's as charge her excellent what commercial will more patient is on bringing many to been as at Melissa its to and color priorities, progress possible. practices. three field of our to the to are healthcare And against her I benefits those perspectives look and on from provide share efforts flows
in physician Before that us I clinical rejoining the to I cost made his scrutinizing Consistent within judiciously. functions we spend leadership, containment company immediate justification acknowledge we introduced new addresses to have to our since with as and an every hiring that requiring progress, curtailed June. with want CFO ensure recent move utilizing of across Driscoll each the Under this, has impact it are Fred all initiatives that our critical and our need. have we aspect important resources
respect provide non-dilutive more estimated OA by addition, shoulder bolstered few a to into XXXX. extends label that shoulder to to OA remains look our play cash OA end ZILRETTA of initiate and year year. a OA. registration a role ZILRETTA in position million expanding while We particularly in progress, the to population minutes. knee is In a track just clinical of shoulder our cycle I'll shoulder runway in the recently ZILRETTA's than color With before and patient fashion, term cash our XXX,XXX loan, this in which improve injections and each activities include meaningful for The life manage their knee financials remain on priority, management pain our function. smaller helping our and Fred refinancing their trial to on pharmacologic X agreement for with market the to versus dearth potential OA treatments of effective addressable a OA, creates total we've roughly
FXXXX is are FXXXX nerve targeted progressing of the formulation pharmacology which Unlike nerve ambulation, a block pain. pipeline, we motor potential we FXXXX relief, of have as least efficiently enhanced following our at hospital of unique blocks, the both rapid selective inhibitor, rehabilitation, our a enable and for thermosensitive investigational, three Regarding and pain while peripheral NaVX.X the days control of preserving funapide, surgery. FXXXX. early from to hydrogel currently post-operative locally to formulation five available believe musculoskeletal discharge in function, deliver effective could administered
functional X and modifying provide also in we enrolled to least potentially high this months FXXXX Based at June, X our single of be We have expand Phase the high fully whether knee in bunionectomy. a for selected low, In this enrolled progression. open X Phase from improvement, made trial study dose of late our are respect investigational, a ascending OA the the dose to to and dose of proof-of-concept administered three is cohort undergoing data, to will doses which of Xb on cohort X evaluating Results disease portion trial patients ascending patients gene year. our FXXXX pain years. two patients. single multi-centered, dose another expected decision trial. aims fully and therapy, by by With locally XX to label mid while The cohorts and FXXXX, relief XX of volume
the In we effusion quarter the mid additional in To-date, adverse addition, treatment and observed first treatment events dose low the injected related XXXX, XX expanded to trial to include both been knee. swelling commonly have most in groups. of the trial the the and in patients in up pain,
intra-articular approach therapies of regimens elicit response. events the to therapies gene means an Vector-based immune strategic prior administration, FXXXX pretreatment investigate to recently AEs these to an are are decision and other the injection of have as immediate with acute known and pretreatment of While potential potentially durability improved these a to immune to with is we steroid made AEs. release tolerable, suppressing investigating mitigating we acute the been way reactivity gene employ similar steroid mitigate
Xst, doses. expect we As patients patients been dose cohorts the of to groups low all to by cohorts, high Committee. the for regimen, soon treat all Monitoring is cleared Data a have up including XX total, treated expansion across the assuming In across XX and an expansion dosing with additional of the August pretreatment mid
data time. activity Melissa. readouts I'll correlation joint Additional endpoints end potential to in fluid are turn anticipated the biological of FXXXX interrogation the it this synovial XXXX, from assess over locally clinical and point, including with over At the by to of patients of
